Supplementary File 3: Quality appraisal Cohort and Cross-Sectional Studies.

Quality Rating Assessment – Observational cohort and cross-sectional studies															
Author (year)	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**Quality rating**
An et al., 2010	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Agirre et al., 2006	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Fellenberg et al., 2010	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Heitzer et al., 2014	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	Y	Good
Je et al., 2013	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Kleiman et al., 2014	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	Y	Good
Levin et al., 2016	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Lin et al., 2015	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Mehdi et al., 2011	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Veeriah et al., 2010	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Deninson et al., 2003	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Letessier et al., 2007	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	Y	Good
Mc Avoy et al., 2007	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Poor
Okochi-Takada et al., 2006	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Poor
Trifa et al., 2013	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Xiang et al., 2012	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Abdelmaksoud-Dammak et al., 2016	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Poor
Cesari et al., 2003	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Li et al., 2015	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Good
Ni et al., 2017	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Sato et al., 2003	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Poor
Wang et al., 2015	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Poor
Nanok et al., 2018	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Poor
Agalliu et al., 2015	Y	Y	NA	Y	Y	NA	Y	NA	Y	N	Y	N	NA	Y	Good
Allegra et al., 2014	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Poor
Inzelberg et al., 2012	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	Y	Good
Ruiz-Martínez et al.,	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Good

2014															
Saunders-Pullman et al., 2010	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	Y	Good
Alcalay et al., 2012	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	N	Fair
Agalliu et al., 2019	Y	Y	NA	Y	N	NA	Y	NA	Y	N	Y	N	NA	Y	Good

Questions:

1. Was the research question or objective in this paper clearly stated?

2. Was the study population clearly specified and defined?

3. Was the participation rate of eligible persons at least 50%?

4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?

5. Was a sample size justification, power description, or variance and effect estimates provided?

6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?

7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?

8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?

9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

10. Was the exposure(s) assessed more than once over time?

11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

12.Were the outcome assessors blinded to the exposure status of participants?

13. Was loss to follow-up after baseline 20% or less?

14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

From: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools

Supplementary References 3.

1. An CH, Kim SS, Kang MR, Kim YR, Kim HS, Yoo NJ, Lee SH. Frameshift mutations of ATBF1, WNT9A, CYLD and PARK2 in gastric and colorectal carcinomas with high microsatellite instability. Pathology. 2010;42(6):583-5
2. Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer. 2006 Apr 15;118(8):1945-53
3. Fellenberg J, Lehner B, Witte D. Silencing of the UCHL1 gene in giant cell tumors of bone. Int J Cancer. 2010 Oct 15;127(8):1804-12
4. Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. Mod Pathol. 2014 Jun;27(6):906-15
5. Je EM, Yoo NJ, Lee SH. Somatic mutation of PARK2 tumor suppressor gene is not common in common solid cancers. Pathol Oncol Res. 2013 Jul;19(3):393-5
6. Kleiman DA, Beninato T, Sultan S, Crowley MJ, Finnerty B, Kumar R, Panarelli NC, Liu YF, Lieberman MD, Seandel M, Evans T, Elemento O, Zarnegar R, Fahey TJ 3rd. Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S672-9
7. Levin L, Srour S, Gartner J, Kapitansky O, Qutob N, Dror S, Golan T, Dayan R, Brener R, Ziv T, Khaled M, Schueler-Furman O, Samuels Y, Levy C. Parkin Somatic Mutations Link Melanoma and Parkinson's Disease. J Genet Genomics. 2016 Jun 20;43(6):369-79
8. Lin DC, Xu L, Chen Y, Yan H, Hazawa M, Doan N, Said JW, Ding LW, Liu LZ, Yang H, Yu S, Kahn M, Yin D, Koeffler HP. Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma. Cancer Res. 2015 May 1;75(9):1815-27
9. Mehdi SJ, Alam MS, Batra S, Rizvi MM. Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma. Med Oncol. 2011 Dec;28(4):1520-6
10. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS,

Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010 Jan;42(1):77-82

11. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer. 2003 Sep;38(1):40-52
12. Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, Adélaïde J, Geneix J, Xerri L, Dubreuil P, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Lopez M, Chaffanet M. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene. 2007 Jan 11;26(2):298-307.
13. McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR, Kosari F, Perez DS, Zhu Y, James CD, Smith DI. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res. 2007;118(2-4):260-9. Review.
14. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer. 2006 Sep 15;119(6):1338-44.
15. Trifa F, Karray-Chouayekh S, Jmaa ZB, Jmal E, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance. Med Oncol. 2013 Mar;30(1):418. doi:10.1007/s12032-012-0418-2.
16. Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, Xiong L, Putti TC, Oberst M, Kelly K, Ren G, Tao Q. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One. 2012;7(1):e29783. doi: 10.1371/journal.pone.0029783.
17. Abdelmaksoud-Dammak R, Saadallah-Kallel A, Miladi-Abdennadher I, Ayedi L, Khabir A, Sallemi-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) and P53 mutation pattern in sporadic colorectal cancer. Tumour Biol. 2016 Feb;37(2):1707-14. doi:10.1007/s13277-015-3902-4.
18. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5956-61.

19. Li WH, Zhang H, Guo Q, Wu XD, Xu ZS, Dang CX, Xia P, Song YC. Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. Dis Markers. 2015;2015:657570. doi: 10.1155/2015/657570.
20. Ni H, Zhou Z, Jiang B, Yuan X, Cao X, Huang G, Li Y. Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma. Tumour Biol. 2017 Mar;39(3):1010428317695025. doi: 10.1177/1010428317695025.
21. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003 Jul 1;63(13):3735-42.
22. Wang G, Zhang W, Zhou B, Jin C, Wang Z, Yang Y, Wang Z, Chen Y, Feng X. The diagnosis value of promoter methylation of UCHL1 in the serum for progression of gastric cancer. Biomed Res Int. 2015;2015:741030. doi: 10.1155/2015/741030.
23. Nanok C, Jearanaikoon P, Proungvitaya S, Limpaiboon T. Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma. Mol Med Rep. 2018 Mar;17(3):4145-4153. doi: 10.3892/mmr.2017.8319.
24. Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.
25. Allegra R, Tunesi S, Cilia R, Pezzoli G, Goldwurm S. LRRK2-G2019S mutation is not associated with an increased cancer risk: a kin-cohort study. Mov Disord. 2014 Sep;29(10):1325-6. doi: 10.1002/mds.25969.
26. Inzelberg R, Cohen OS, Aharon-Peretz J, Schlesinger I, Gershoni-Baruch R, Djaldetti R, Nitsan Z, Ephraty L, Tunkel O, Kozlova E, Inzelberg L, Kaplan N, Fixler Mehr T, Mory A, Dagan E, Schechtman E, Friedman E, Hassin-Baer S. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology. 2012 Mar 13;78(11):781-6. doi:10.1212/WNL.0b013e318249f673.
27. Ruiz-Martínez J, de la Riva P, Rodríguez-Oroz MC, Mondragón Rezola E, Bergareche A, Gorostidi A, Gago B, Estanga A, Larrañaga N, Sarasqueta C, López de Munain A, Martí Massó JF. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. Mov Disord. 2014 May;29(6):750-5. doi:10.1002/mds.25778.

28. Saunders-Pullman R, Barrett MJ, Stanley KM, Luciano MS, Shanker V, Severt L, Hunt A, Raymond D, Ozelius LJ, Bressman SB. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord. 2010 Nov 15;25(15):2536-41. doi: 10.1002/mds.23314.
29. Alcalay RN, Clark LN, Marder KS, Bradley WE. Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families. Genes Chromosomes Cancer. 2012 Dec;51(12):1109-13. doi:10.1002/gcc.21995.
30. Agalliu I, Ortega RA, Luciano MS, Mirelman A, Pont-Sunyer C, Brockmann K, Vilas D, Tolosa E, Berg D, Warø B, Glickman A, Raymond D, Inzelberg R, Ruiz-Martinez J, Mondragon E, Friedman E, Hassin-Baer S, Alcalay RN, Mejia-Santana H, Aasly J, Foroud, T, Marder K, Giladi N, Bressman S, and Saunders-Pullman R. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Mov. Disord. 2019;4:1392–1398.

Genetic Parkinsonism and Cancer: A Systematic Review and Meta-Analysis

Andrea Sturchio, Alok K. Dwivedi, Joaquin A. Vizcarra, Martina Chirra, Elizabeth G. Keeling, Ignacio F. Mata, Marcelo A. Kauffman, Manoj K. Pandey, Giandomenico Roviello, Cristoforo Comi, Maurizio Versino, Luca Marsili*, Alberto J. Espay.

*Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH; marsilla@ucmail.uc.edu.